1
|
Su CH, Jeng JS, Tu ST, Huang CN, Yeh HI. An Effective Strategy to Activate Physicians to Promote High Cardiovascular Risk Patients to Quit Smoking. Acta Cardiol Sin 2022; 38:521-525. [PMID: 35873124 PMCID: PMC9295038 DOI: 10.6515/acs.202207_38(4).20220224a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 02/24/2022] [Indexed: 12/14/2022]
Abstract
BACKGROUND Adult patients cared for by cardiologists, neurologists, and diabetologists are highly vulnerable to cardiovascular diseases (CVDs), which are worsened by smoking. In the past, physicians of these three specialties at major hospitals in Taiwan always referred patients to family medicine and chest medicine departments for smoking cessation programs. However, the participation rate in these programs was unsatisfactory. OBJECTIVES To encourage cardiologists, neurologists, and diabetologists to provide smoking cessation treatment services (SCTSs) to their patients through an annual contest. METHODS Sequential expert meetings, group training, a contest to reward service quantity and abstinence rate, and an annual awards ceremony were held over the past 3 years. RESULTS More than 350 cardiologists, neurologists, and diabetologists were certified to provide SCTSs, and in the second half of 2020, 3716 high CVD risk patients entered smoking cessation treatment programs, with an abstinence rate exceeding 30% at 3 months. CONCLUSIONS The strategy used in this study was effective in overcoming physician inertia to provide SCTSs and encourage high CVD risk smokers to quit smoking.
Collapse
Affiliation(s)
- Cheng-Huang Su
- Cardiovascular Center, MacKay Memorial Hospital, Taipei & MacKay Medical College, New Taipei City
| | - Jiann-Shing Jeng
- Stroke Center and Department of Neurology, National Taiwan University Hospital, Taipei
| | - Shih-Te Tu
- Endocrinology & Metabolism Division, Changhua Christian Hospital, Changhua
| | - Chien-Ning Huang
- Institute of Medicine, Chung Shan Medical University & Hospital, Taichung, Taiwan
| | - Hung-I Yeh
- Cardiovascular Center, MacKay Memorial Hospital, Taipei & MacKay Medical College, New Taipei City
| |
Collapse
|
2
|
Bayram F, Sonmez A, Haymana C, Sabuncu T, Dizdar OS, Gurkan E, Carlioglu AK, Agbaht K, Ozdemir D, Demirci I, Barcin C, Salman S, Tetiker T, Balci MK, Kebapci N, Ersoy C, Yumuk V, Toth PP, Satman I. Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study). Lipids Health Dis 2020; 19:237. [PMID: 33176832 PMCID: PMC7659134 DOI: 10.1186/s12944-020-01408-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Accepted: 10/19/2020] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Attaining acceptable levels of LDL Cholesterol (LDL-C) significantly improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM). The LDL-C target attainment and the characteristics of patients attaining these targets were investigated in this study. Furthermore, the reasons for not choosing statins and the physicians' attitudes on the treatment of diabetic dyslipidemia were also examined. METHODS A nationwide, cross-sectional survey was conducted in tertiary centers for diabetes management. Adult patients with T2DM, who were under follow-up for at least a year in outpatient clinics, were consecutively enrolled for the study. LDL-C goals were defined as below 70 mg/dL for patients with macrovascular complications or diabetic nephropathy, and below 100 mg/dL for other patients. Data about lipid-lowering medications were self-reported. RESULTS A total of 4504 patients (female: 58.6%) were enrolled for the study. The mean HbA1c and diabetes duration was 7.73 ± 1.74% and 10.9 ± 7.5 years, respectively. The need for statin treatment was 94.9% (n = 4262); however, only 42.4% (n = 1807) of these patients were under treatment, and only 24.8% (n = 448) of these patients achieved LDL-C targets. The main reason for statin discontinuation was negative media coverage (87.5%), while only a minority of patients (12.5%) mentioned side effects. Physicians initiated lipid-lowering therapy in only 20.3% of patients with high LDL-C levels. It was observed that the female gender was a significant independent predictor of not attaining LDL-C goals (OR: 0.70, 95% CI: 0.59-0.83). CONCLUSIONS Less than 50 % of patients with T2DM who need statins were under treatment, and only a quarter of them attained their LDL-C targets. There exists a significant gap between the guideline recommendations and the real-world evidence in the treatment of dyslipidemia in T2DM.
Collapse
Affiliation(s)
- Fahri Bayram
- Department of Endocrinology and Metabolism, Erciyes University, School of Medicine, Kayseri, Turkey
| | - Alper Sonmez
- Department of Endocrinology and Metabolism, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkey
| | - Cem Haymana
- Department of Endocrinology and Metabolism, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
| | - Tevfik Sabuncu
- Department of Endocrinology and Metabolism, Harran University, School of Medicine, Sanliurfa, Turkey
| | - Oguzhan Sitki Dizdar
- Department of Endocrinology and Metabolism, Kayseri Training and Research Hospital, Kayseri, Turkey
| | - Eren Gurkan
- Department of Endocrinology and Metabolism, Mustafa Kemal University, School of Medicine, Hatay, Turkey
| | - Ayse Kargili Carlioglu
- Department of Endocrinology and Metabolism, Erzurum Training and Research Hospital, Erzurum, Turkey
| | - Kemal Agbaht
- Department of Endocrinology and Metabolism, Private Defne Hospital, Hatay, Turkey
| | - Didem Ozdemir
- Department of Endocrinology and Metabolism, Yildirim Beyazit University, School of Medicine, Ankara, Turkey
| | - Ibrahim Demirci
- Department of Endocrinology and Metabolism, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey
| | - Cem Barcin
- Department of Cardiology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkey
| | - Serpil Salman
- Department of Endocrinology and Metabolism, Private Liv Hospital, Istanbul, Turkey
| | - Tamer Tetiker
- Department of Endocrinology and Metabolism, Cukurova University, School of Medicine, Adana, Turkey
| | - Mustafa Kemal Balci
- Department of Endocrinology and Metabolism, Akdeniz University, School of Medicine, Antalya, Turkey
| | - Nur Kebapci
- Department of Endocrinology and Metabolism, Osmangazi University, School of Medicine, Eskisehir, Turkey
| | - Canan Ersoy
- Department of Endocrinology and Metabolism, Uludag University, School of Medicine, Bursa, Turkey
| | - Volkan Yumuk
- Department of Endocrinology and Metabolism, Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey
| | - Peter P Toth
- Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,Preventive Cardiology, CGH Medical Center, Sterling, IL, USA
| | - Ilhan Satman
- Department of Endocrinology and Metabolism, Istanbul University, School of Medicine, Istanbul, Turkey
| | | |
Collapse
|